Cantargia - Kempens Catalyst picks for Q2'21
-
Fra Kempens Industri rapport - Life Scienes - update Q2 2021
Cantargia: Update PDAC (pot. at ASCO) could trigger sentiment recovery
We initiated coverage on Cantargia just a few weeks after seeing the share price taking a hard hit following a phase III failure of competitor Novartis.
We see limited read-through to Cantargia and deem the sell-off overdone, asi) lead compound CAN04 has a broader mode of action compared to Novartis'canakinumab, and ii) the setting where Novartis failed (2L/3L NSCLC) is are cognizable difficult indication, currently not key to the CAN04 story.
In our view,the main indication for CAN04 is 1L PDAC, where we see a straight path forward backed by encouraging interim phase II data showing that a combination with GA in1L PDAC resulted in partial responses in 8/20 patients (40% ORR).
Updated results (incl. more patients, PFS, DOR, biomarkers) are expected in H1'21 (pot. at ASCO).These results will not only be used to design a pivotal phase III trial, but we alsobelieve meaningful PFS and/or DOR (historically in this setting ~23% ORR, mOS8.5m, mPFS 5.5m) could trigger the stock to make up lost ground.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind